Review



seldi‐tof proteinchip reader  (Ciphergen inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Ciphergen inc seldi‐tof proteinchip reader
    Comparison of human tear proteome studies concerning patients affected by ocular diseases
    Seldi‐Tof Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/proteinchip+seldi+tof+ms+analysis/pmc09543345-11-29-30
    Average 90 stars, based on 1 article reviews
    seldi‐tof proteinchip reader - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery"

    Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

    Journal: Mass Spectrometry Reviews

    doi: 10.1002/mas.21691

    Comparison of human tear proteome studies concerning patients affected by ocular diseases
    Figure Legend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

    Techniques Used: Software, Biomarker Assay

    Comparison of human tear proteome studies concerning patients affected by systemic diseases
    Figure Legend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

    Techniques Used: Software

    Related Articles

    SDS Page:

    Article Title: Nitrated alpha-synuclein and microglial neuroregulatory activities
    Article Snippet: Following stimulation, supernatants were removed and added to cultures of MES23.5 cells for an additional 24 h. MES 23.5 cell viability was assessed using the Live/Dead cytotoxicity assay (Invitrogen) as previously described ( Reynolds et al., 2007b ).

    Western Blot:

    Article Title: Nitrated alpha-synuclein and microglial neuroregulatory activities
    Article Snippet: Following stimulation, supernatants were removed and added to cultures of MES23.5 cells for an additional 24 h. MES 23.5 cell viability was assessed using the Live/Dead cytotoxicity assay (Invitrogen) as previously described ( Reynolds et al., 2007b ).

    Molecular Weight:

    Article Title: Nitrated alpha-synuclein and microglial neuroregulatory activities
    Article Snippet: Following stimulation, supernatants were removed and added to cultures of MES23.5 cells for an additional 24 h. MES 23.5 cell viability was assessed using the Live/Dead cytotoxicity assay (Invitrogen) as previously described ( Reynolds et al., 2007b ).

    Liquid Chromatography with Mass Spectroscopy:

    Article Title: Nitrated alpha-synuclein and microglial neuroregulatory activities
    Article Snippet: Following stimulation, supernatants were removed and added to cultures of MES23.5 cells for an additional 24 h. MES 23.5 cell viability was assessed using the Live/Dead cytotoxicity assay (Invitrogen) as previously described ( Reynolds et al., 2007b ).



    Similar Products

    seldi-tof ms proteinchip system  (Bio-Rad)
    90
    Bio-Rad seldi-tof ms proteinchip system
    Seldi Tof Ms Proteinchip System, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/proteinchip+seldi+system/pmc09960765-153-6-10
    Average 90 stars, based on 1 article reviews
    seldi-tof ms proteinchip system - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    proteinchip system 4000 seldi-tof mass spectrometer  (Bio-Rad)
    90
    Bio-Rad proteinchip system 4000 seldi-tof mass spectrometer
    CART analysis using peaks obtained by SELDI-TOF-MS to discriminate between patients with MMD and control patients. The decision tree was constructed using CSF samples from 32 patients with MMD and control patients. The classification is determined starting at the roof node, following by appropriate splitting decisions based on the peak intensity at each node. If the peak intensity is lower than the cutoff intensity value, the left node is selected. This splitting process is continued until no further classification is achieved and terminal nodes are produced. Using m/z 4473, 2406 and 6338 peaks (pH 5), m/z 4588 and 7250 peaks (pH 7), and m/z 4746 and 1044 peaks (pH 9), CART for Q10 <t>ProteinChip</t> was applied to identify patients with MMD and control patients. The analysis correctly classified all 20 patients with MMD under pH 5 condition and 19 of 20 under the pH 7 and 9 conditions; all 12 control patients were classified under all pH conditions.
    Proteinchip System 4000 Seldi Tof Mass Spectrometer, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/ProteinChip+Protein+Calibrant+Kit/pmc02992492-104-8-16
    Average 90 stars, based on 1 article reviews
    proteinchip system 4000 seldi-tof mass spectrometer - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    seldi‐tof proteinchip reader  (Ciphergen inc)
    90
    Ciphergen inc seldi‐tof proteinchip reader
    Comparison of human tear proteome studies concerning patients affected by ocular diseases
    Seldi‐Tof Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/proteinchip+seldi+tof+ms+analysis/pmc09543345-11-29-30
    Average 90 stars, based on 1 article reviews
    seldi‐tof proteinchip reader - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    seldi‐tof proteinchip reader pbs ii  (Ciphergen inc)
    90
    Ciphergen inc seldi‐tof proteinchip reader pbs ii
    Comparison of human tear proteome studies concerning patients affected by ocular diseases
    Seldi‐Tof Proteinchip Reader Pbs Ii, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/pbs+ii+seldi+tof+mass+spectrometer/pmc09543345-20-30-31
    Average 90 stars, based on 1 article reviews
    seldi‐tof proteinchip reader pbs ii - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    proteinchip® seldi-tof reader pcs4000 ms-tof enterprise  (Bio-Rad)
    90
    Bio-Rad proteinchip® seldi-tof reader pcs4000 ms-tof enterprise
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip® Seldi Tof Reader Pcs4000 Ms Tof Enterprise, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/ProteinChip+Protein+Calibrant+Kit/pmc06325504-130-6-12
    Average 90 stars, based on 1 article reviews
    proteinchip® seldi-tof reader pcs4000 ms-tof enterprise - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    proteinchip® seldi reader pcs4000 ms-tof enterprise  (Bio-Rad)
    90
    Bio-Rad proteinchip® seldi reader pcs4000 ms-tof enterprise
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip® Seldi Reader Pcs4000 Ms Tof Enterprise, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/pcs+4000/pm29778662-75-6-12
    Average 90 stars, based on 1 article reviews
    proteinchip® seldi reader pcs4000 ms-tof enterprise - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    seldi-tof-ms proteinchip array profiling systems  (Ciphergen inc)
    90
    Ciphergen inc seldi-tof-ms proteinchip array profiling systems
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Seldi Tof Ms Proteinchip Array Profiling Systems, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/proteinchip+seldi+tof+ms+analysis/us09791449-945-45-53
    Average 90 stars, based on 1 article reviews
    seldi-tof-ms proteinchip array profiling systems - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    proteinchip system, series 4000 seldi-tof mass spectrometer  (Ciphergen inc)
    90
    Ciphergen inc proteinchip system, series 4000 seldi-tof mass spectrometer
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip System, Series 4000 Seldi Tof Mass Spectrometer, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/proteinchip+reader+maldi+tof+mass+spectrometer/us09675664-111-12-19
    Average 90 stars, based on 1 article reviews
    proteinchip system, series 4000 seldi-tof mass spectrometer - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    q10 array proteinchip seldi tof analysis  (Bio-Rad)
    93
    Bio-Rad q10 array proteinchip seldi tof analysis
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Q10 Array Proteinchip Seldi Tof Analysis, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/seldi-tof+proteinchip+%C2%AE+assays/ProteinChip+Q10+Arrays/pm26613366-115-5-21
    Average 93 stars, based on 1 article reviews
    q10 array proteinchip seldi tof analysis - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    CART analysis using peaks obtained by SELDI-TOF-MS to discriminate between patients with MMD and control patients. The decision tree was constructed using CSF samples from 32 patients with MMD and control patients. The classification is determined starting at the roof node, following by appropriate splitting decisions based on the peak intensity at each node. If the peak intensity is lower than the cutoff intensity value, the left node is selected. This splitting process is continued until no further classification is achieved and terminal nodes are produced. Using m/z 4473, 2406 and 6338 peaks (pH 5), m/z 4588 and 7250 peaks (pH 7), and m/z 4746 and 1044 peaks (pH 9), CART for Q10 ProteinChip was applied to identify patients with MMD and control patients. The analysis correctly classified all 20 patients with MMD under pH 5 condition and 19 of 20 under the pH 7 and 9 conditions; all 12 control patients were classified under all pH conditions.

    Journal: BMC Neurology

    Article Title: Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS

    doi: 10.1186/1471-2377-10-112

    Figure Lengend Snippet: CART analysis using peaks obtained by SELDI-TOF-MS to discriminate between patients with MMD and control patients. The decision tree was constructed using CSF samples from 32 patients with MMD and control patients. The classification is determined starting at the roof node, following by appropriate splitting decisions based on the peak intensity at each node. If the peak intensity is lower than the cutoff intensity value, the left node is selected. This splitting process is continued until no further classification is achieved and terminal nodes are produced. Using m/z 4473, 2406 and 6338 peaks (pH 5), m/z 4588 and 7250 peaks (pH 7), and m/z 4746 and 1044 peaks (pH 9), CART for Q10 ProteinChip was applied to identify patients with MMD and control patients. The analysis correctly classified all 20 patients with MMD under pH 5 condition and 19 of 20 under the pH 7 and 9 conditions; all 12 control patients were classified under all pH conditions.

    Article Snippet: The protein mass spectral data was generated with ProteinChip System 4000 SELDI-TOF mass spectrometer (Enterprise version; Bio-Rad Laboratories) using automated data collection protocol with Ciphergen Express version 3.0.6 software interface (Bio-Rad Laboratories).

    Techniques: Construct, Produced

    Comparison of human tear proteome studies concerning patients affected by ocular diseases

    Journal: Mass Spectrometry Reviews

    Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

    doi: 10.1002/mas.21691

    Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

    Article Snippet: Grus et al. ( ) , DED , Single subject, 1 take , STS , 20 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Ciphergen Express Data Manager , N/D.

    Techniques: Software, Biomarker Assay

    Comparison of human tear proteome studies concerning patients affected by systemic diseases

    Journal: Mass Spectrometry Reviews

    Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

    doi: 10.1002/mas.21691

    Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

    Article Snippet: Grus et al. ( ) , DED , Single subject, 1 take , STS , 20 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Ciphergen Express Data Manager , N/D.

    Techniques: Software

    Comparison of human tear proteome studies concerning patients affected by ocular diseases

    Journal: Mass Spectrometry Reviews

    Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

    doi: 10.1002/mas.21691

    Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

    Article Snippet: Tomosugi et al. ( ) , DED, SS , Single subject, 1 take , STS , 24 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Biomarker Wizard , 56.

    Techniques: Software, Biomarker Assay

    Comparison of human tear proteome studies concerning patients affected by systemic diseases

    Journal: Mass Spectrometry Reviews

    Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

    doi: 10.1002/mas.21691

    Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

    Article Snippet: Tomosugi et al. ( ) , DED, SS , Single subject, 1 take , STS , 24 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Biomarker Wizard , 56.

    Techniques: Software

    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

    Journal: American Journal of Translational Research

    Article Title: Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients

    doi:

    Figure Lengend Snippet: Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

    Article Snippet: ProteinChip®-captured proteins were detected using a ProteinChip® SELDI-TOF reader PCS4000 MS-TOF Enterprise (Bio-Rad).

    Techniques: MANN-WHITNEY